Rachelle Salomon, Ph.D.


Dr. Rachelle Salomon joined the National Cancer Institute (NCI) in 2017 as a program director in the Biological Resources Branch in the Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis (DCTD). Dr. Salomon manages NCI grants and contracts including the development of novel biologic therapies by the Biopharmaceutical Development Program (BDP) at the Frederick National Laboratory for Cancer Research (FNLCR). The BDP provides process development, cGMP manufacturing, process analytics, quality assurance and regulatory support for biologics. Currently Dr. Salomon is managing the development of antibodies, vaccines, and cell therapy products for treatment of patients in phase I clinical trials. Several of these drugs are part of the NCI Experimental Therapeutics (NExT) Program which advances promising cancer therapies from bench to bedside. Prior to NCI, she served as a program officer for influenza and SARS-associated coronavirus (SARS-CoV) vaccine research and development at the National Institute of Allergy and Infectious Diseases (NIAID) for eight years. As health science administrator, Dr. Salomon has served as the scientific lead on clinical trials, the Contracting Officer Representative (COR) III for contracts developing biologics and animal models, and the subject matter expert (SME) or representative on interagency committees and international delegations. Dr. Salomon earned her PhD in immunology at Brown University in the laboratory of Dr. Christine Biron, PhD, DFAAI, where she became enthralled by the delicate balance between protective and pathogenic immune responses. These scientific interests lead her to study influenza pathogenesis and immunity during her postdoctoral fellowship with Dr. Robert Webster, PhD, DSc, FRS, NAS at St. Jude Children’s Research Hospital.